Paul H. Edelstein

Paul H. Edelstein

Auto-generated profile, based on publicly available information

Paul H. Edelstein

Medical Research Council Laboratory of Molecular Biology

Research Focus & Metrics

Academic Career Length

52Years (1975-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2001 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ELEbbing Lautenbach
Ebbing Lautenbach
JPJean Baldus Patel
Jean Baldus Patel
WBWarren B. Bilker
Warren B. Bilker
PEPaul H. Edelstein
Paul H. Edelstein
NFNeil O. Fishman
Neil O. Fishman
The prevalence of antibiotic resistance among extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae has increased

1 April 2011 in Cell
Verified
Journal Article
Closed access
KAKristin N. Adams
Kristin N. Adams
KTKevin Takaki
Kevin Takaki
LCLynn E. Connolly
Lynn E. Connolly
HWHeather Wiedenhoft
Heather Wiedenhoft
KWKathryn Winglee
Kathryn Winglee
LRLalita Ramakrishnan
Lalita Ramakrishnan

1 December 2009 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
LGLeanne B. Gasink
Leanne B. Gasink
PEPaul H. Edelstein
Paul H. Edelstein
ELEbbing Lautenbach
Ebbing Lautenbach
MSMarie Synnestvedt
Marie Synnestvedt
NFNeil O. Fishman
Neil O. Fishman
Background.: Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae is an emerging pathogen with serious clinical and infection control implications. To our knowledge, no study has specifically examined risk factors for KPC-producing K. pneumoniae or its impact on mortality.Methods.: To identify risk factors for infection or colonization with KPC-producing K. pneumoniae, a case-control study was performed. Case patients with KPC-producing K. pneumoniae were compared with control subjects with carbapenem-susceptible K. pneumoniae. A cohort study evaluated the association between KPC-producing K. pneumoniae and in-hospital mortality.Results.: Fifty-six case patients and 863 control subjects were identified. In multivariable analysis, independent risk factors for KPC-producing K. pneumoniae were (1) severe illness (adjusted odds ratio [AOR], 4.31; 95% confidence interval [CI], 2.25–8.25), (2) prior fluoroquinolone use (AOR, 3.39; 95% CI, 1.50, 7.66), and (3) prior extended-spectrum cephalosporin use (AOR, 2.55; 95% CI, 1.18, 5.52). Compared with samples from other anatomic locations, K. pneumoniae isolates from blood samples were less likely to harbor KPC (AOR, 0.33; 95% CI, 0.12, 0.86). KPC-producing K. pneumoniae was independently associated with in-hospital mortality (AOR, 3.60; 95% CI, 1.87–6.91).Conclusions.: KPC-producing K. pneumoniae is an emerging pathogen associated with significant mortality. Our findings highlight the urgent need to develop strategies for prevention and infection control. Limiting use of certain antimicrobials, specifically fluoroquinolones and cephalosporins, use may be effective strategies.

20 March 2007 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
LCLynn E Connolly
Lynn E Connolly
PEPaul H Edelstein
Paul H Edelstein
LRLalita Ramakrishnan
Lalita Ramakrishnan
The authors argue that understanding and countering general bacterial mechanisms of phenotypic antibiotic resistance may hold the key to reducing the duration of treatment of all recalcitrant bacterial infections, including tuberculosis.

15 July 1992 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
MLMark S. Lachs
Mark S. Lachs
INIrving Nachamkin
Irving Nachamkin
PEPaul H. Edelstein
Paul H. Edelstein
JGJay Goldman
Jay Goldman
AFAlvan R. Feinstein
Alvan R. Feinstein
JSJ. Sanford Schwartz
J. Sanford Schwartz
To determine if the leukocyte esterase and bacterial nitrite rapid dipstick test for urinary tract infection (UTI) is susceptible to spectrum bias (when a diagnostic test has different sensitivities or specificities in patients with different clinical manifestations of the disease for which the test is intended). Cross-sectional study. A total of 366 consecutive adult patients in whom clinicians performed urinalysis to diagnose or exclude UTI. An urban emergency department and walk-in clinic. After the patient encounter, but before dipstick test or culture was done, clinicians recorded the signs and symptoms that were the basis for suspecting UTI and for performing a urinalysis and an estimate of the probability of UTI based on the clinical evaluation. For all patients who received urinalysis, dipstick tests and culture were done in the clinical microbiology laboratory by medical technologists blinded to clinical evaluation. Sensitivity for the dipstick was calculated using a positive result in either leukocyte esterase or bacterial nitrite, or both, as the criterion for a positive dipstick, and greater than 10(5) CFU/mL for a positive culture. In the 107 patients with a high (greater than 50%) prior probability of UTI, who had many characteristic UTI symptoms, the sensitivity of the test was excellent (0.92; 95% CI, 0.82 to 0.98). In the 259 patients with a low (less than or equal to 50%) prior probability of UTI, the sensitivity of the test was poor (0.56; CI, 0.03 to 0.79). The leukocyte esterase and bacterial nitrite dipstick test for UTI is susceptible to spectrum bias, which may be responsible for differences in the test's sensitivity reported in previous studies. As a more general principle, diagnostic tests may have different sensitivities or specificities in different parts of the clinical spectrum of the disease they purport to identify or exclude, but studies evaluating such tests rarely report sensitivity and specificity in subgroups defined by clinical symptoms. When diagnostic tests are evaluated, information about symptoms in the patients recruited for study should be included, and analyses should be done within appropriate clinical subgroups so that clinicians may decide if reported sensitivities and specificities are applicable to their patients.

1 June 1993 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
PEPaul H. Edelstein
Paul H. Edelstein
Paul H. Edelstein; Legionnaires' Disease, Clinical Infectious Diseases, Volume 16, Issue 6, 1 June 1993, Pages 741–749, https://doi.org/10.1093/clind/16.6.741